Sign in Subscribe
United States. Securities and Exchange Commission

Vertex Pharmaceuticals Inc. Files SEC Form 4, Disclosure by Officer - Director

Strategic Insights

— 1 min read

Vertex Pharmaceuticals Inc., a leading developer of innovative medicines for the treatment of serious diseases, recently filed a Form 4 document with the U.S. Securities and Exchange Commission (SEC). The filing, which was received on February 27, 2015, provides detailed information about the company's equity securities and the beneficial ownership of its directors and officers. As a publicly-traded company, Vertex Pharmaceuticals is subject to regular SEC filings, which are designed to promote transparency and accountability in the financial markets.

Key Takeaways:

  • The Form 4 filing is a disclosure by an officer or director of Vertex Pharmaceuticals, indicating a change in beneficial ownership of the company's equity securities.
  • The filing was submitted on February 27, 2015, and contains information about the reporting person's relationship to the company, as well as purchases and sales of equity securities.
  • As a pharmaceutical company, Vertex Pharmaceuticals is subject to strict regulations and guidelines, including those related to equity security ownership and disclosure.
  • The SEC filing is publicly available on the EDGAR database, allowing investors and stakeholders to access the information they need to make informed decisions about the company.
  • The filing is a required part of the company's reporting obligations under Section 12 of the Securities Exchange Act of 1934.

Statistics:

  • The SIC code for Vertex Pharmaceuticals Inc. is 2834, indicating that the company operates in the pharmaceutical preparations industry.
  • The company's contact information, as listed in the SEC filing, is 50 NORTHERN AVENUE, BOSTON MA 02210, with a phone number of 6173416393.
  • The SEC filing number for this document is 0001209191-15-019541, and the EDGAR database filing ID is 0001209191-15-019541.
  • Data on the number of beneficial owners of Vertex Pharmaceuticals stock is not provided in the source material.

Sources:

  • NewsRx LLC (2015). Vertex Pharmaceuticals Inc. Files SEC Form 4, Disclosure by Officer - Director. Retrieved from
  • U.S. Securities and Exchange Commission (n.d.). Form 4 - Statement of changes in beneficial ownership of securities. Retrieved from

Read more